Amgen Inc. (NASDAQ:AMGN): Closing price $105.60
After it did not obtain the clinical trial data it requested, Amgen is pressing to pay less than the $130 a share it offered earlier in August for Onyx Pharmaceuticals Inc., according to inside sources, who added that Onyx refused to give Amgen additional data on its blood-cancer treatment Kyprolis. Amgen wanted the data so as to more accurately value the drug, the sources said last week, and one indicated that Onyx does not want to give out the data in part because they pertain to individual patients. The sources also said that Amgen has not put out a new offer and is considering its next move.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.